KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Palvella Therapeutics (PVLA) Interest & Investment Income (2017 - 2022)

Palvella Therapeutics (PVLA) has disclosed Interest & Investment Income for 9 consecutive years, with $169000.0 as the latest value for Q3 2024.

  • On a quarterly basis, Interest & Investment Income fell 69.22% to $169000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $1.1 million, a 39.04% decrease, with the full-year FY2023 number at $1.9 million, up 156.73% from a year prior.
  • Interest & Investment Income was $169000.0 for Q3 2024 at Palvella Therapeutics, down from $201000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $549000.0 in Q3 2023 to a low of -$6000.0 in Q4 2021.
  • A 5-year average of $194578.9 and a median of $169000.0 in 2024 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: tumbled 200.0% in 2022, then skyrocketed 12000.0% in 2023.
  • Palvella Therapeutics' Interest & Investment Income stood at $8000.0 in 2020, then tumbled by 175.0% to -$6000.0 in 2021, then surged by 5950.0% to $351000.0 in 2022, then increased by 29.63% to $455000.0 in 2023, then crashed by 62.86% to $169000.0 in 2024.
  • Per Business Quant, the three most recent readings for PVLA's Interest & Investment Income are $169000.0 (Q3 2024), $201000.0 (Q2 2024), and $240000.0 (Q1 2024).